

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

5-1-2023

Neurosteroids as stress modulators and neurotherapeutics: Lessons from the retina

Yukitoshi Izumi

Washington University School of Medicine in St. Louis

Makoto Ishikawa

Tohoku University

Toru Nakazawa

Tohoku University

Hiroshi Kunikata

Tohoku University

Kota Sato

Tohoku University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Recommended Citation

Izumi, Yukitoshi; Ishikawa, Makoto; Nakazawa, Toru; Kunikata, Hiroshi; Sato, Kota; Covey, Douglas F.; and Zorumski, Charles F., "Neurosteroids as stress modulators and neurotherapeutics: Lessons from the retina." *Neural Regeneration Research*. 18, 5. 1004 - 1008. (2023).

https://digitalcommons.wustl.edu/oa_4/626

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Yukitoshi Izumi, Makoto Ishikawa, Toru Nakazawa, Hiroshi Kunikata, Kota Sato, Douglas F. Covey, and Charles F. Zorumski

Neurosteroids as stress modulators and neurotherapeutics: lessons from the retina

Yukitoshi Izumi^{1, #}, Makoto Ishikawa^{2, 3, #}, Toru Nakazawa^{2, 3, 4, 5}, Hiroshi Kunikata^{3, 4}, Kota Sato^{2, 5}, Douglas F. Covey^{1, 6}, Charles F. Zorumski^{1, *}

<https://doi.org/10.4103/1673-5374.355752>

Date of submission: May 16, 2022

Date of decision: July 1, 2022

Date of acceptance: July 21, 2022

Date of web publication: October 10, 2022

From the Contents

Introduction	1004
Search Strategy and Selection Criteria	1004
Relevance of the Retina and Glaucoma to Neuropsychiatry	1004
An Ex Vivo Retinal Preparation and Glaucoma Model	1005
Neurosteroids and Effects of High Pressure in the Retina	1005
Lessons Learned from the Retina	1007
Future Directions in Neurosteroid Pharmacology	1007

Abstract

Neurosteroids are rapidly emerging as important new therapies in neuropsychiatry, with one such agent, brexanolone, already approved for treatment of postpartum depression, and others on the horizon. These steroids have unique properties, including neuroprotective effects that could benefit a wide range of brain illnesses including depression, anxiety, epilepsy, and neurodegeneration. Over the past 25 years, our group has developed *ex vivo* rodent models to examine factors contributing to several forms of neurodegeneration in the retina. In the course of this work, we have developed a model of acute closed angle glaucoma that involves incubation of *ex vivo* retinas under hyperbaric conditions and results in neuronal and axonal changes that mimic glaucoma. We have used this model to determine neuroprotective mechanisms that could have therapeutic implications. In particular, we have focused on the role of both endogenous and exogenous neurosteroids in modulating the effects of acute high pressure. Endogenous allopregnanolone, a major stress-activated neurosteroid in the brain and retina, helps to prevent severe pressure-induced retinal excitotoxicity but is unable to protect against degenerative changes in ganglion cells and their axons under hyperbaric conditions. However, exogenous allopregnanolone, at a pharmacological concentration, completely preserves retinal structure and does so by combined effects on gamma-aminobutyric acid type A receptors and stimulation of the cellular process of macroautophagy. Surprisingly, the enantiomer of allopregnanolone, which is inactive at gamma-aminobutyric acid type A receptors, is equally retinoprotective and acts primarily via autophagy. Both enantiomers are also equally effective in preserving retinal structure and function in an *in vivo* glaucoma model. These studies in the retina have important implications for the ongoing development of allopregnanolone and other neurosteroids as therapeutics for neuropsychiatric illnesses.

Key Words: allopregnanolone; autophagy; enantiomers; excitotoxicity; gamma-aminobutyric acid type A receptors; glaucoma; optic nerve; oxysterols

Introduction

Neurosteroids are important modulators of neuronal stress and use a variety of mechanisms to help neurons establish homeostasis following insults. Neurosteroids are synthesized endogenously in the brain from cholesterol or sterol precursors, and are a subset of a broader class of steroids that modulate brain function, referred to as neuroactive steroids (NAS) (Paul and Purdy, 1992). Increasing evidence indicates the importance of NAS as therapeutics for neuropsychiatric illnesses (Zorumski et al., 2013), and has led to FDA approval of brexanolone, for treatment of postpartum depression (Meltzer-Brody and Kanes, 2020). Brexanolone is a formulation of the neurosteroid, allopregnanolone (AlloP), in cyclodextrin (Captisol) for intravenous infusion. Another NAS, zuranolone, is in late-stage human trials for postpartum depression and major depression (Gunduz-Bruce et al., 2019; Deligiannidis et al., 2021). The approval of brexanolone has prompted increasing interest in understanding mechanisms contributing to the action of AlloP and related NAS. For over 25 years, our group has examined models of neuronal injury and stress in retinal preparations and these studies provide new insights into the actions of AlloP as both an endogenous stress modulator and as a pharmacological therapeutic. In this review, we describe our studies in the retina, with emphasis on glaucoma models, and ways in which this work may inform use of NAS in neuropsychiatry.

Search Strategy and Selection Criteria

This review focuses upon work done in our laboratories over an extended period that includes the development of an *ex vivo* retinal preparation for studying various forms of retinal degeneration including extension to a model of glaucoma. To put this work in context of the field, our review of the literature used PubMed as the search engine with search terms that

included retina, glaucoma, neurosteroids, and excitotoxicity, focusing on work pertinent to the experiments described.

Relevance of the Retina and Glaucoma to Neuropsychiatry

Multiple neuropsychiatric illnesses involve changes in axons and white matter in the brain. These include neurodegenerative illnesses such as Alzheimer's and Huntington's diseases, but also primary psychiatric illnesses including schizophrenia, major depression, and autism, among others (Fields, 2008; Alnaes et al., 2018). Axonal changes contribute to altered connectivity within and across brain regions underlying mental functions of cognition, emotion, and motivation, and can be observed early in the course of illness, particularly in disorders with developmental origins. Given that glaucoma involves damage to retinal ganglion cells (RGCs) and their axons that form the optic nerve, glaucoma could provide insights into understanding axonal dysfunction and its treatment. Glaucoma is the second leading cause of blindness worldwide and the number one cause of blindness among African Americans. Glaucoma is also associated with more than two-fold increase in major depression (Yoshikawa et al., 2019).

A second reason for interest in the retina involves increasing evidence that RGCs mediate effects of light on mood and behavior, including risk of depression. It is now clear that there are multiple subtypes of RGCs, including RGCs that express melanopsin and have intrinsic photosensitivity (ip) akin to photoreceptors (Tran et al., 2019). Different subtypes of ipRGCs connect to different subcortical regions and mediate unique behavioral effects (Fernandez et al., 2018; Do, 2019). One subclass connects to the suprachiasmatic nucleus and secondarily to the hippocampus, mediating effects of light on learning and memory (Fernandez et al., 2018; Huang et al., 2021). A

¹Department of Psychiatry and Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA; ²Department of Ophthalmic Imaging and Information Analytics, Tohoku University Graduate School of Medicine, Sendai, Japan; ³Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan; ⁴Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Sendai, Japan; ⁵Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; ⁶Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA

*Correspondence to: Charles F. Zorumski, MD, zorumskc@wustl.edu.

<https://orcid.org/0000-0002-9704-5154> (Charles F. Zorumski)

#Both authors contributed equally to this work.

Funding: This work was supported by MH101874, MH114866, MH122379 from the National Institute of Mental Health (to CFZ); the Taylor Family Institute for Innovative Psychiatric Research and the Bantley Foundation (to CFZ).

How to cite this article: Izumi Y, Ishikawa M, Nakazawa T, Kunikata H, Sato K, Covey DF, Zorumski CF (2023) Neurosteroids as stress modulators and neurotherapeutics: lessons from the retina. *Neural Regen Res* 18(5):1004-1008.

second subtype connects to the perihabenular region and secondarily to the dorsomedial striatum and nucleus accumbens to mediate effects of light on mood (Fernandez et al., 2018; Huang et al., 2019). Other studies indicate that ipRGCs drive a light-activated pathway to ventral lateral geniculate and the intergeniculate leaflet that results in inhibition of lateral habenula and mediates antidepressant effects of light, a finding of importance for seasonal mood disorders and disorders of circadian rhythms (Huang et al., 2019).

An Ex Vivo Retinal Preparation and Glaucoma Model

Work in the retina has had a major impact on understanding mechanisms of neurodegeneration, particularly glutamate-mediated excitotoxicity. Some of the earliest work on glutamate toxicity came from observations in the retina (Lucas and Newhouse, 1957) and was later extended to the brain by John Olney (Olney, 1969). In the 1980s, Olney and colleagues used an *ex vivo* embryonic chick retinal preparation to define mechanisms underlying glutamate-induced excitotoxicity (Olney et al., 1986, 1990; Romano et al., 1998). Because of limitations of the chick model including challenges in doing studies across a range of ages, Yukitoshi Izumi developed an *ex vivo* model for these studies using rat retinas (Izumi et al., 1995a). This model proved useful for histological studies across a range of developmental ages (Izumi et al., 1995b) including work on the effects of excitotoxic conditions on Muller glial cells (Izumi et al., 2003) and the role of glutamate transporters (Izumi et al. 2002). Other studies examined the mechanisms of various forms of retinal phototoxicity (Tokuda et al., 2007, 2009).

In the early 2000s, Makoto Ishikawa and colleagues adapted the *ex vivo* rat preparation to study the effects of elevated pressure as a model of acute closed angle glaucoma. The initial model incubated retinas under conditions designed to mimic acute increases in hydrostatic pressure. For these studies, retinal eye cups from 30-day-old rats were incubated at the bottom of cylinders filled to varying degrees with oxygenated artificial cerebral spinal fluid (ACSF) to mimic normal pressure (10 mmHg), moderately elevated pressure (35 mmHg) and high pressure (75 mmHg) (Ishikawa 2010; **Figure 1**). Retinas incubated under normobaric conditions exhibited intact retinal histology with no evidence of damage. However, retinas incubated for 24 hours at 75 mmHg exhibited damage to RGCs (shrinkage) and swollen axons of these neurons without significant injury to other retinal layers (Ishikawa et al., 2010, 2011). Damage to the optic nerve head was also observed. Importantly, damage caused by high pressure differed distinctly from excitotoxic damage produced by glutamate or AMPA under normobaric conditions (Ishikawa et al., 2010), and was histologically distinct from the effects of simulated ischemia (oxygen-glucose deprivation) (Izumi et al., 2003; **Figure 2**). Nonetheless, damage to RGCs and axonal swelling resulting from hyperbaric incubation was blocked completely by a combination of glutamate receptor antagonists acting at NMDA and non-NMDA ionotropic receptors (Ishikawa et al., 2010).

The initial glaucoma model described above was an open hydrostatic system in which pressure on the retinal eyecups was controlled by the height of fluid in the incubation cylinders. This model had several limitations and was eventually replaced by a closed incubation system in which volume in the chamber was kept constant and pressure was regulated by influx and efflux of gas (95% oxygen-5% carbon dioxide) via separate valves, using a manometer to monitor intra-chamber pressure (Ishikawa et al., 2016; **Figure 1**). Retinas were incubated in standard volumes of ACSF for 24 hours and showed similar changes in RGCs and axons in response to hyperbaric pressure without damage to other retinal layers.

Neurosteroids and Effects of High Pressure in the Retina

Why neurosteroids?

Neurosteroids, including AlloP, are synthesized locally from cholesterol in excitatory neurons and glia cells in response to a variety of stressors. In the hippocampus, these stressors include metabolic insults (altered energy metabolism) and toxins (ethanol and acetaldehyde) along with the stress hormone, corticosterone (Zorumski and Izumi, 2012; Zorumski et al., 2014). Importantly these stressors cause acute accumulation of glutamate and tonic activation of NMDA receptors (Tokuda et al., 2011). Even brief exposures to these stressors (5–30 minutes) cause untimely activation of NMDA receptors and, as a result, impair induction of long-term potentiation (LTP) in the CA1 hippocampal region through an NMDA receptor-mediated form of metaplasticity (Zorumski and Izumi, 2012). These changes occur in the absence of histological damage or changes in baseline synaptic transmission, but involve upregulation of the synthesis of 5-alpha reduced neurosteroids, particularly AlloP. These observations, coupled with the role of cellular stress (high pressure) and glutamate in the glaucoma model, led us to consider whether AlloP and other sterols might be important modulators of stress on retinal structure and function, serving perhaps as homeostatic neuroprotective mechanisms. Furthermore, the retina is neurosteroidogenic and RGCs express key enzymes in neurosteroid synthesis including CYP11A1, a mitochondrial cholesterol side chain cleavage enzyme that generates pregnenolone as the first step in neurosteroid synthesis (Guarneri et al., 1994, 1998, 2003; Cascio et al., 2015). RGCs express other steroidogenic proteins including the 18 kDa translocator protein, TSPO, as well as 5-alpha reductase (5AR), a key synthetic enzyme (Ishikawa et al., 2016).

Neurosteroids as neuroprotectants

Because of the therapeutic potential of AlloP and other NAS, we initially examined whether exogenous AlloP alters injury to RGCs and axons in the nerve fiber layer (NFL). Co-incubation of retinas for 24 hours with high pressure and varying concentrations of AlloP resulted in concentration-dependent retinal protection. At 10 nM AlloP, there was no clear change in pressure-induced damage; some neuroprotection was observed at 100 nM, with complete retinal preservation at 1 μ M (Ishikawa et al., 2014), a concentration above physiological levels.

In related studies, we examined the role of endogenous AlloP in modulating effects of high pressure. Using liquid chromatography and tandem mass spectrometry to measure AlloP, we found very low levels of the steroid under basal conditions when retinas were incubated for 24 hours at 10 mm Hg. At 35 mm Hg, only marginal increases of AlloP were observed, while incubation at 75 mm Hg resulted in 60–70-fold increases in AlloP compared to normobaric conditions (Ishikawa et al., 2014). These increases in AlloP at high pressure were partially inhibited (approximately 50% reduction) by finasteride, a 5AR antagonist that acts at a subset of 5ARs. More complete inhibition was observed with dutasteride, a broader spectrum 5AR antagonist (Pinacho-Garcia et al., 2020), and with the competitive NMDA receptor antagonist, 2-amino-5-phosphonoverlate (Ishikawa et al., 2014). Using an antibody against 5-alpha-reduced steroids that primarily recognizes AlloP (Tokuda et al., 2010, 2011), we also observed immunohistochemical evidence of increases in neurosteroids in RGCs; these changes were dampened by the antagonists described above (Ishikawa et al., 2014).

Changes in neurosteroid levels led us to consider whether endogenous 5-alpha-reduced steroids play a protective role in the retina under stress. When retinas were incubated with 5AR antagonists under normobaric conditions, no significant histological changes were observed. However, 5AR antagonists led to marked damage in multiple retinal layers during exposure to high pressure. These latter changes included RGC and axonal damage as well as excitotoxic changes in other retinal layers. Excitotoxic changes included marked swelling of neurons resulting in “bull’s-eye” appearances of cells in the inner nuclear layer (INL) and “swiss-cheese” (edematous) changes in the inner plexiform layer. This severe excitotoxicity was blocked by the NMDA receptor antagonist, 2-amino-5-phosphonoverlate, and by exogenous AlloP at 1 μ M (Ishikawa et al., 2014).

We also found that high pressure increases expression of genes and proteins thought to be involved in neurosteroidogenesis, including TSPO and 5AR. Increases in 5AR, mostly type II, a form of the enzyme inhibited by dutasteride and finasteride (Pinacho-Garcia et al., 2020), were observed in RGCs and INL (Ishikawa et al., 2016), consistent with what we observed with changes in AlloP levels described above. TSPO has a complex relationship to steroidogenesis. While it is clearly a protein of importance for mitochondrial function, its role in neurosteroid synthesis is less certain based on studies in TSPO knockout mice (Selvaraj et al., 2015), although other studies suggest some role in neurosteroidogenesis (Tokuda et al., 2010; Ishikawa et al., 2016; Mages et al., 2019).

How is AlloP neuroprotective? Roles of gamma-aminobutyric acid-A receptors and autophagy

AlloP is a complex neuromodulator produced on-demand under stressful conditions in the brain and nervous system. It has several known mechanisms that could contribute to neuroprotection. Most prominently, AlloP is a potent and effective positive allosteric modulator (PAM) of gamma-aminobutyric acid (GABA)-A receptors, the receptors that mediate the majority of fast inhibitory transmission (Zorumski et al., 2019). Potentiation of GABA-A receptors occurs at mid-nanomolar concentrations; at higher nanomolar to micromolar concentrations, AlloP can directly open GABA-A channels in the absence of GABA (called direct channel gating). GABA-A receptors are heteropentamers with 19 subunits identified (Belelli and Lambert, 2005). Different subtypes of GABA-A receptors are expressed at synapses where they mediate phasic forms of inhibition. Other GABA-A receptors are expressed at extrasynaptic sites where they sense ambient levels of GABA and mediate tonic inhibition (Belelli et al., 2009). Importantly, AlloP and related NAS modulate both phasic and tonic inhibition, giving them the unique ability to regulate the balance of excitation and inhibition throughout the brain. Thus, modulation of GABA transmission is a major mechanism likely contributing to the effects of AlloP. Beyond GABA, AlloP also has effects on other ion channels and intracellular processes. These include inhibition of low voltage-activated (T-type) calcium channels that mediate burst firing in certain neurons and help to regulate oscillatory firing and pain (Pathirathna et al., 2005). AlloP is a highly lipophilic steroid and accesses intracellular compartments where it modulates inflammation (Balan et al., 2019, 2021), mitochondrial function, and energy utilization (Grimm et al., 2014).

We examined the role of GABA-A receptors in the effects of AlloP in our glaucoma model using picrotoxin, a non-competitive GABA-A receptor antagonist. The protective effects of exogenous AlloP were completely blocked by co-administration of picrotoxin, indicating a prominent role for GABA-A receptors in neuroprotection. In addition to overcoming protection of RGCs and axons in the NFL, picrotoxin promoted more severe damage in the retina including excitotoxic changes in the INL and inner plexiform layer (Ishikawa et al., 2014).

Because neuroprotective effects of AlloP in other studies involve mechanisms in addition to GABA-A receptor modulation (Langmade et al., 2006), we also




Figure 1 | The diagram depicts methods for *ex vivo* rat retinal studies including the methods used to mimic glaucoma.

Steps in the procedure are outlined. (1) An eye is removed from the orbits of a decapitated rat. (2) The eye is placed in a holding device on the fixed floor of a petri dish filled with chilled artificial cerebral spinal fluid. (3) The anterior segments and vitreous are carefully removed. (4) The eyecup (retina and sclera) is positioned at the bottom of a tall glass cylinder filled with artificial cerebrospinal fluid for 24 hours. The bottom of the chamber is bathed at 30°C. (5) Alternatively, the eyecup in gassed artificial cerebral spinal fluid is placed in a closed pressure-loading chamber for 24 hours.




Figure 2 | Retinal histology in the *ex vivo* model.

(A) A control retina from a postnatal day 30 rat, incubated in artificial cerebral spinal fluid at 30°C for 24 hours shows largely intact structure. (B) Incubation at 75 mmHg for 24 hours results in marked axonal swelling in the retinal ganglion cell layer (bottom). (C) In contrast, incubation for 1 hour in a simulated ischemia condition (oxygen-glucose deprivation) results in severe excitotoxic damage characterized by bulls-eye appearances in the INL and Swiss-cheese-like changes in the IPL. Scale bar: 50 μ m. GCL: Ganglion cell layer; INL: inner nuclear layer; IPL: inner plexiform layer; OLM: outer limiting membrane; ONL: outer nuclear layer; OPL: outer plexiform layer. Unpublished data.

examined whether alternative mechanisms contribute to effects in the retina focusing on the possible role of macroautophagy (autophagy). Autophagy is a mechanism by which cells recycle debris to help control stress responses, preserve energy and promote survival, although, when unchecked, excessive autophagy can also lead to cell death (Kroemer et al., 2010; Zhou et al., 2019). Under hyperbaric conditions, AlloP increased levels of the lipidated form of microtubule-associated protein 1 light chain 3 beta (LC3B-II) and decreased levels of sequestosome 1 (p62), consistent with enhancement of autophagy. At the ultrastructural level, AlloP increased the number of autophagosomes and degenerative autophagic vacuoles in the NFL. Inhibitors of autophagy, including bafilomycin A1 and SAR405, overcame the protective effects of AlloP and induced severe neurodegeneration. Autophagy activators, rapamycin and

Torin 2, produced partial protection against high pressure, consistent with a protective role of autophagy in our model (Ishikawa et al., 2021).

Taken together, these results indicate that effects on GABA-A receptors and activation of autophagy contribute to retinal protection by AlloP in the *ex vivo* glaucoma model (Figure 3). Whether other actions of AlloP contribute to retinal preservation remains uncertain, but are areas for further investigation.

AlloP & Retinal Protection




Figure 3 | AlloP and effects of high pressure on the retina.

The diagram depicts findings described in this paper including the role of stress (high pressure), glutamate, NMDARs and synthesis of endogenous AlloP. Full protection by exogenous AlloP and ent-AlloP, and the roles of GABA-A receptors and autophagy are also depicted. The dashed arrow indicates that other mechanisms likely contribute to the pathophysiology of glaucomatous changes. SAR: 5 Alpha reductase; AlloP: allopregnanolone; Ent-AlloP: enantiomer of allopregnanolone; GABA-ARs: GABA-A receptors; NMDARs: N-methyl-D-aspartate receptors; RGC: retinal ganglion cells.

The enantiomer of AlloP is also neuroprotective in the retina

In an effort to determine the importance of GABA-A receptor PAM activity in neuroprotection by AlloP, we used its unnatural enantiomer (ent-AlloP). Earlier work demonstrated that effects of AlloP on GABA-A receptors are highly enantioselective with the enantiomers differing by at least an order of magnitude in potency (Wittmer et al., 1996; Covey et al., 2001). However, enantiomers accumulate identically in cell membranes and intracellular compartments (Chisari et al., 2009, 2010; Jiang et al., 2016). To our surprise, but consistent with a prior study in a model of developmental neurodegeneration (Langmade et al., 2006), we found that ent-AlloP was at least as effective as AlloP in protecting the retina from damage produced by high pressure at an equimolar concentration (1 μ M). Furthermore, and consistent with its lack of effects on GABA-A receptors, retinal protection by ent-AlloP was not altered by picrotoxin, unlike natural AlloP (Ishikawa et al., 2022). However, ent-AlloP increased the number of autophagosomes and degenerative autophagic vacuoles in the NFL, and enhanced protein levels of LC3B-II while decreasing levels of p62, indicating that ent-AlloP, like AlloP, promotes autophagy. The autophagy inhibitor, 3-methyladenine, blocked neuroprotection by ent-AlloP, but did not alter protection by AlloP. This latter result is intriguing and suggests that it is possible to dissociate the role of GABA-A receptors (or other mechanisms) from autophagy in the effects of natural AlloP. Furthermore, these results indicate that ent-AlloP promotes autophagy as a major mechanism of retinal protection, but these effects are independent of GABA-A receptors in contrast to AlloP (Figure 3). In direct comparisons using biochemical markers of autophagy, ent-AlloP appears to be more effective than AlloP in activating autophagy at a concentration of each that is fully neuroprotective (Ishikawa et al., 2022). We note that there is presently controversy concerning the role of autophagy in glaucoma and other neurodegenerative illnesses (Spalding et al., 2005; Kroemer et al., 2010), but there is considerable interest in whether agents targeting this mechanism can be developed for use in neuropsychiatric illnesses (Hui et al., 2021). Additionally, the targets and mechanisms by which NAS stimulates autophagy remain undefined, and it is presently unclear whether autophagy is a primary action or the result of another modulated cellular process.

AlloP enantiomers are protective in an *in vivo* glaucoma model

To determine whether effects observed in the *ex vivo* glaucoma model translate to animals, we used a rat model of increased intraocular pressure (IOP) produced by intracameral injection of polystyrene microbeads. In this model, IOP increases from about 10 mmHg to 30 mmHg over 3 days after bead injection and IOP remains elevated at this level for the remainder of the three-week experiment (Ishikawa, 2021, 2022). In control rats, elevated IOP results in damage to RGCs and axons in the NFL by 21 days after injection. Animals also exhibit impaired visual responses as measured by the retinal scotopic threshold response. Effects of AlloP and ent-AlloP were examined using a single injection of the steroids on day 7 after bead injection, at a time when elevated IOP was fully established. The steroids were solubilized in β -cyclodextrin and administered as a 1 μ L injection into the vitreous using a 0.05% (w/v) saline solution. Neither steroid altered the increase in IOP caused by microbead injections. Nonetheless, both enantiomers produced strong neuroprotection based on histology and measures of apoptosis of RGCs, and both promoted autophagy based on measures outlined in the *ex vivo* studies above. Similarly, both steroids preserved the retinal scotopic threshold response, indicating preserved visual function as well as histology (Ishikawa et al., 2021, 2022).

Lessons Learned from the Retina

Studies in the retina raise several important considerations for therapeutic use of neurosteroids in neuropsychiatric illnesses. Below we outline several key points that we take from the studies described. We provide additional commentary for certain points that may be relevant to considering how neurosteroids are used clinically going forward.

1. Rodent retinal models are useful for understanding mechanisms contributing to neurodegeneration and neuroprotection. In particular, the *ex vivo* system provides a useful tool for detailed mechanistic studies.

2. Neurosteroids, particularly AlloP, are important endogenous modulators that help to preserve neuronal structure and function under stressful conditions. This is likely true throughout the brain as it is in the retina.

3. Extracellular glutamate accumulation and tonic activation of NMDA receptors are key drivers of the effects of stress on synthesis of neurosteroids. This has been observed in both retina and hippocampus.

4. Removal of acute protection by endogenous 5- α reduced steroids renders neurons highly vulnerable to excitotoxic neurodegeneration involving multiple retinal layers. However, there are limits on neuroprotection provided by endogenous AlloP, as evidenced by glaucomatous changes even in the presence of increases in endogenous neurosteroid.

5. Pharmacological effects of neurosteroids are required for full neuroprotection, even in the presence of elevated endogenous steroid levels. These pharmacological effects may require concentrations above those that are considered physiological as evidenced by full protection with 1 μ M but not 100 nM exogenous AlloP. Furthermore, a single injection of neurosteroid at a pharmacological dose can have lasting neuroprotective effects *in vivo* even when the primary neuronal stressor (high pressure) persists. We note that current use of brexanolone (AlloP) for postpartum depression involves a 60-hour infusion in which the dose is escalated to a high level observed in pregnancy (approximately 100 nM) and maintained at that level for 28 hours before tapering off by the end of infusion (Meltzer-Brody and Kanes, 2020). Another NAS, zuranolone, is administered orally as a single, 30–50 mg daily dose (Gunduz-Bruce et al., 2019; Deligiannidis et al., 2021). Levels achieved by these steroids and duration of exposure at high levels in key brain regions may be important in determining clinical efficacy, and high doses may be required for maximal results, based on studies in the retina. It is also intriguing that even transient and perhaps intermittent exposures to GABAergic NAS can have persisting effects both in the glaucoma model and in humans with major depressive syndromes. These observations make it important to understand the longer-term effects of NAS following transient exposures; studies in the retina can help this effort based on results to date.

6. The enantiomer of AlloP is an intriguing pharmacological tool, providing unexpected neuroprotection via the cellular mechanism of autophagy. Neuroprotection by ent-AlloP does not involve effects on GABA-A receptors and may thus obviate certain side effects of AlloP including sedation and loss of consciousness, perhaps allowing administration of higher doses. Metabolism of ent-AlloP and other enantiomeric steroids will likely differ from AlloP and possibly contribute to longer-lived effects. Side effects of enantiomeric neurosteroids are presently unknown. A diagram of the roles of endogenous and exogenous AlloP in the studies described is shown in **Figure 3**. We also note that in our *in vivo* glaucoma model (Ishikawa et al., 2021; 2022) and in a model of developmental neurodegeneration (Langmade et al., 2006), both AlloP enantiomers provide neuroprotection following a single administration that persists for weeks in rodents, while having no effect on the causative mechanisms that underlie neuropathology.

Future Directions in Neurosteroid Pharmacology

Neuroprotective effects of both endogenous and exogenous AlloP in the retina are unequivocal. Future studies are required to define the full mechanisms by which neurosteroids produce their protective effects including the role of GABA-A receptors and alternative targets. It is presently unclear how AlloP and its enantiomer stimulate autophagy, but it is clear that GABA-A receptors are not the entire story, particularly for ent-AlloP. Based on work with AlloP analogues that are photoaffinity labels, both endogenous and exogenously applied NAS interact with several known intracellular targets. These steroids interact strongly with Golgi and this interaction, as well as intracellular and membranous accumulation, is not enantioselective (Jiang et al., 2016). Specific intracellular targets identified to date include the microtubule protein, β -tubulin, at Cys-354 (Chen et al., 2012), and the mitochondrial proteins voltage-dependent anion channel-1 and -2 (VDAC) at Glu-73 of VDAC-1 along with four additional sites (Darbandi-Tonkabon et al., 2003, 2004; Budelier et al., 2017; Cheng et al., 2019). The site on β -tubulin is shared by colchicine, and the VDAC-1 sites are shared with cholesterol (Budelier et al., 2019). These are potentially important intracellular targets that could play a role in neuroprotection, but their roles in effects of NAS are still undefined. Earlier studies indicated no role for VDACS in GABA-A receptor effects of NAS or anesthesia (Darbandi-Tonkabon et al., 2004) and NAS do not alter gating of VDAC-1 (Cheng et al., 2019). Ongoing work with photoaffinity labels will no doubt identify other targets.

Going forward, it will be important to define other mechanisms that contribute to homeostatic and protective effects of NAS. In particular, neuroinflammation is a mechanism contributing to the pathogenesis of neuropsychiatric illnesses including retinal disorders. Increasing evidence indicates that NAS, and AlloP in particular, have anti-inflammatory effects that may be important for therapeutic effects (Balan et al., 2019, 2021). Other potential contributors could include effects on cellular stress responses including the folded protein response and integrated stress response.

Autophagy interacts with integrated stress response, making this an intriguing potential target (Kroemer et al., 2010). It will also be important to define more clearly the role of GABA-A receptor modulation in the effects of AlloP and whether the enantiomers have additive or synergistic effects when applied in combination. It is also unknown at present whether mechanisms other than GABA-A receptors contribute to psychotropic actions.

This review has focused almost exclusively on AlloP and its enantiomer. While AlloP is a major cholesterol-derived neuromodulator, a host of other steroids are produced in the retina and brain (Guarneri et al., 2003; Belelli and Lambert, 2005). Some of these agents have unique properties including effects on other ion channels, receptors, and intracellular targets. Additionally, the class of side chain oxidized derivatives of cholesterol (oxysterols) are also neuromodulators with 24S-hydroxycholesterol (24S-HC) being the major metabolite of cholesterol in the brain (Sun et al., 2016). 24S-HC has multiple effects including potent and effective PAM activity at NMDA receptors (Paul et al., 2013). This oxysterol has complex effects on neurons including bidirectional effects on neurotoxicity. In some studies, 24S-HC fosters neurodegeneration, as would be expected of an NMDAR PAM, while in other studies this oxysterol is neuroprotective (Sun et al., 2016). In the *ex vivo* glaucoma model, we found 24S-HC is neuroprotective by mechanisms that are not yet defined. Akin to AlloP, synthesis of 24S-HC via CYP46A1 appears to be stress-activated in response to reactive oxygen species (Sodero et al., 2011) and plays a role in regulating autophagy (Nobrega et al., 2019). An analogue of 24S-HC, SAGE-718, is currently in clinical trials as a cognitive enhancer in Huntington's, Parkinson's and Alzheimer's diseases. Another oxysterol, 25-hydroxycholesterol is also intriguing as a modulator of neuroinflammation, and is synthesized in the brain primarily in microglia (Wong et al., 2020; Izumi et al., 2021); 25-hydroxycholesterol also has weak partial agonist PAM effects on NMDA receptors and can serve as a functional inhibitor of 24S-HC (Linsenbardt et al., 2014).

In summary, studies in the retina clarify some of the protective mechanisms of AlloP and offer potential to identify other important effects going forward. It also appears that we are presently only scratching the surface of cholesterol-derived modulators and their potential roles as therapeutics in neuropsychiatry, including how these modulators interact to promote neuronal homeostasis.

Acknowledgments: The authors thank Ann Benz and Kazuko Izumi from the Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA for technical assistance, and members of the Taylor Family Institute, St. Louis, MO, USA for helpful comments and advice.

Author contributions: YI, MI and CFZ conceived, designed and wrote the manuscript. All authors edited and revised the paper and approved the final version of the manuscript.

Conflicts of interest: CFZ serves on the Scientific Advisory Board of Sage Therapeutics. DFC was a co-founder of Sage Therapeutics. DFC and CFZ have equity in Sage Therapeutics. Sage Therapeutics did not fund this research. Other authors have no conflicts to declare.

Availability of data and materials: All data generated or analyzed during this study are included in this published article and its supplementary information files.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Open peer reviewer: Yasushi Kitaoka, St. Marianna University School of Medicine, Japan.

Additional file: Open peer review report 1.

References

- Alnaes D, Kaufmann T, Doan NT, Cordova-Palomera A, Wang Y, Bettella F, Moberget T, Andreassen OA, Westlye LT (2018) Association of heritable cognitive ability and psychopathology with white matter properties in children and adolescents. *JAMA Psychiatry* 75:287-295.
- Balan I, Beattie MC, O'Buckley TK, Aurelian L, Morrow AL (2019) Endogenous neurosteroid (3 α ,5 α)3-hydroxypregnan-20-one inhibits toll-like-4 receptor activation and pro-inflammatory signaling in macrophages and brain. *Sci Rep* 9:1220.
- Balan I, Aurelian L, Schleicher R, Boero G, O'Buckley T, Morrow AL (2021) Neurosteroid allopregnanolone (3 α ,5 α -THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors. *Transl Psychiatry* 11:145.
- Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABAA receptor. *Nat Rev Neurosci* 6:565-575.
- Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW (2009) Extrasynaptic GABAA receptors: form, pharmacology, and function. *J Neurosci* 29:12757-12763.
- Budelier MM, Cheng WWL, Bergdoll L, Chen ZW, Janetka JW, Abramson J, Krishnan K, Mydock-McGrane L, Covey DF, Whitelegge JP, Evers AS (2017) Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1. *J Biol Chem* 292:9294-9304.

- Budelier MM, Cheng WWL, Chen ZW, Bracamontes JR, Sugawara Y, Krishnan K, Mydock-McGrane L, Covey DF, Evers AS (2019) Common binding sites for cholesterol and neurosteroids on a pentameric ligand-gated ion channel. *Biochim Biophys Acta Mol Cell Biol Lipids* 1864:128-136.
- Cascio C, Deidda I, Russo D, Guarneri P (2015) The estrogenic retina: the potential contribution to healthy aging and age-related neurodegenerative diseases of the retina. *Steroids* 103:31-41.
- Chen ZW, Chen LH, Akentjeva N, Lichti CF, Darbandi R, Hastings R, Covey DF, Reichert DE, Townsend RR, Evers AS (2012) A neurosteroid analogue photolabeling reagent labels the colchicine-binding site on tubulin: a mass spectrometric analysis. *Electrophoresis* 33:666-674.
- Cheng WWL, Budelier MM, Sugawara Y, Bergdoll L, Queralto-Martín M, Rosencrans W, Rostovtseva TK, Chen ZW, Abramson J, Krishnan K, Covey DF, Whiteledge JP, Evers AS (2019) Multiple neurosteroid and cholesterol binding sites in voltage-dependent anion channel-1 determined by photo-affinity labeling. *Biochim Biophys Acta Mol Cell Biol Lipids* 1864:1269-1279.
- Chisari M, Eisenman LN, Krishnan K, Bandyopadhyaya AK, Wang C, Taylor A, Benz A, Covey DF, Zorumski CF, Mennerick S (2009) The influence of neuroactive steroid lipophilicity on GABA_A receptor modulation: evidence for a low affinity interaction. *J Neurophysiol* 102:1254-1264.
- Chisari M, Eisenman LN, Covey DF, Mennerick S, Zorumski CF (2010) The sticky issue of neurosteroids and GABA_A receptors. *Trends Neurosci* 33:299-306.
- Covey DF, Evers AS, Mennerick S, Zorumski CF, Purdy RH (2001) Recent developments in structure-activity relationships for steroid modulators of GABA(A) receptors. *Brain Res Rev* 37:91-97.
- Darbandi-Tonkabar N, Hastings WR, Zeng C-M, Akk G, Manion BD, Bracamontes JR, Steinbach JH, Mennerick SJ, Covey DF, Evers AS (2003) Photoaffinity labeling with a neuroactive steroid analogue. 6-azi-pregnanolone labels voltage-dependent anion channel-1 in rat brain. *J Biol Chem* 278:13196-13206.
- Darbandi-Tonkabar N, Manion BD, Hastings WR, Craigjen WJ, Akk G, Bracamontes JR, He Y, Sheiko TV, Steinbach JH, Mennerick SJ, Covey DF, Evers AS (2004) Neuroactive steroid interactions with voltage-dependent anion channels: lack of relationship to GABA_A receptor modulation and anesthesia. *J Pharmacol Exp Ther* 308:502-511.
- Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of zuranolone vs placebo in postpartum depression – a randomized clinical trial. *JAMA Psychiatry* 78:951-959.
- Do MTH (2019) Melanopsin and the intrinsically photosensitive retinal ganglion cells: biophysics to behavior. *Neuron* 104:205-226.
- Fernandez DC, Fogerson M, Ospri LL, Thomsen MB, Layne RM, Severin D, Zhan J, Singer JH, Kirkwood A, Zhao H, Berson DM, Hattar S (2018) Light affects mood and learning through distinct retina-brain pathways. *Cell* 175:71-84.
- Fields RD (2008) White matter in learning, cognition and psychiatric disorders. *Trends Neurosci* 31:361-370.
- Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A (2014) Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders. *Biochim Biophys Acta* 1842:2427-2438.
- Guarneri P, Guarneri R, Cascio C, Pavasant P, Piccoli F, Papadopoulos V (1994) Neurosteroidogenesis in rat retinas. *J Neurochem* 63:86-96.
- Guarneri P, Russo D, Cascio C, De Leo G, Piccoli F, Guarneri R (1998) Induction of neurosteroid synthesis by NMDA receptors in isolated rat retina: a potential early event in excitotoxicity. *Eur J Neurosci* 10:1752-1763.
- Guarneri P, Cascio C, Russo D, D'Agostino S, Drago G, Galizzi G, De Leo G, Piccoli F, Guarneri M, Guarneri R (2003) Neurosteroids in the retina: neurodegenerative and neuroprotective agents in retinal degeneration. *Ann N Y Acad Sci* 1007:117-128.
- Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riessenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ (2019) Trial of SAGE-217 in patients with major depressive disorder. *N Engl J Med* 381:903-911.
- Huang L, Xi Y, Peng Y, Huang X, Fu Y, Tao Q, Xiao J, Yuan T, An K, Zhao H, Pu M, Xu F, Xue T, Luo M, So KF, Ren C (2019) A visual circuit related to habenula underlies the antidepressant effects of light therapy. *Neuron* 102:128-142.
- Huang X, Huang P, Huang L, Hu Z, Liu X, Shen J, Xi Y, Yang Y, Fu Y, Tao Q, Lin S, Xu A, Xu F, Xue T, So K-F, Li H, Ren C (2021) A visual circuit related to nucleus reuniens for the spatial-memory-promoting effects of light treatment. *Neuron* 109:347-362.
- Hui KK, Endo R, Sawa A, Tanaka M (2021) A perspective on the potential involvement of impaired proteostasis in neuropsychiatric disorders. *Biol Psychiatry* 91:335-345.
- Ishikawa M, Yoshitomi T, Zorumski CF, Izumi Y (2010) Effects of acutely elevated hydrostatic pressure in a rat ex vivo retinal preparation. *Invest Ophthalmol Vis Sci* 51:6414-6423.
- Ishikawa M, Yoshitomi T, Zorumski CF, Izumi Y (2014) Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model. *Invest Ophthalmol Vis Sci* 55:8531-8541.
- Ishikawa M, Yoshitomi T, Zorumski CF, Izumi Y (2016a) TSPO activation modulates the effects of high pressure in a rat ex vivo glaucoma model. *Neuropharmacology* 111:142-159.
- Ishikawa M, Takaseki S, Yoshitomi T, Covey DF, Zorumski CF, Izumi Y (2021) The neurosteroid allopregnanolone protects retinal neurons by effects on autophagy and GABRs/GABA_A receptors in rat glaucoma models. *Autophagy* 17:743-760.
- Ishikawa M, Nakazawa T, Kunikata H, Sato K, Yoshitomi T, Krishnan K, Covey DF, Zorumski CF, Izumi Y (2022) The enantiomer of allopregnanolone prevents pressure-mediated retinal degeneration via autophagy. *Front Pharmacol* 13:855779.
- Izumi Y, Benz AM, Kirby CO, Labruyere J, Zorumski CF, Price MT, Olney JW (1995a) An ex vivo rat retinal preparation for excitotoxicity studies. *J Neurosci Methods* 60:219-225.
- Izumi Y, Kirby-Sharkey CO, Benz AM, Labruyere J, Price MT, Wozniak DF, Zorumski CF, Olney JW (1995b) Age dependent sensitivity of the rat retina to the excitotoxic action of N-methyl-D-aspartate. *Neurobiol Dis* 2:139-144.
- Izumi Y, Shimamoto K, Benz AM, Hammerman SB, Olney JW, Zorumski CF (2002) Glutamate transporters and retinal excitotoxicity. *Glia* 39:58-69.
- Izumi Y, Hammerman SB, Kirby CO, Benz AM, Olney JW, Zorumski CF (2003) Involvement of glutamate in ischemic neurodegeneration in isolated retina. *Vis Neurosci* 20:97-107.
- Izumi Y, Cashikar AG, Krishnan K, Paul SM, Covey DF, Mennerick SJ, Zorumski CF (2021) A proinflammatory stimulus disrupts hippocampal plasticity and learning via microglial activation and 25-hydroxycholesterol. *J Neurosci* 41:10054-10064.
- Jiang X, Shu H-J, Krishnan K, Qian M, Taylor AA, Covey DF, Zorumski CF, Mennerick S (2016) A clickable neurosteroid photolabel reveals selective Golgi compartmentalization with preferential impact on proximal inhibition. *Neuropharmacology* 108:193-206.
- Kroemer G, Marino G, Levine B: Autophagy and the integrated stress response (2010) *Molec Cell* 40:280-293.
- Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE, Ory DS (2006) Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. *Proc Natl Acad Sci U S A* 103:13807-13812.
- Linsendardt AJ, Taylor A, Emmett CM, Doherty JJ, Krishnan K, Covey DF, Paul SM, Zorumski CF, Mennerick S (2014) Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. *Neuropharmacology* 85:232-242.
- Lucas DR, Newhouse JP (1957) The toxic effect of sodium L-glutamate on the inner layers of the retina. *AMA Arch Ophthalmol* 58:193-201.
- Mages K, Grassmann F, Jäggle H, Rupprecht R, Weber BHF, Hauck SM, Grosche A (2019) The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia. *J Neuroinflammation* 16:43.
- Meltzer-Brody S, Kanes SJ (2020) Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. *Neurobiol Stress* 12:100212.
- Nobrega C, Mendonca L, Marcelo A, Lamaziere A, Tome S, Despres G, Matos CA, Mechet F, Langui D, den Dunnen W, de Almeida LP, Cartier N, Alves S (2019) Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. *Acta Neuropathol* 138:837-858.
- Olney JW (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science* 164:719-721.
- Olney JW, Price MT, Samson L, Labruyere J (1986) The role of specific ions in glutamate neurotoxicity. *Neurosci Lett* 65:65-71.
- Olney JW, Zorumski C, Price MT, Labruyere J (1990) L-cysteine, a bicarbonate-sensitive endogenous excitotoxin. *Science* 248:596-599.
- Pathirathna S, Brimelow BC, Jagodic MM, Krishnan K, Jiang X, Zorumski CF, Mennerick S, Covey DF, Todorovic SM, Jevtic-Todorovic V (2005) New evidence that both T-type calcium channels and GABA_A channels are responsible for the potent analgesic effects of 5α-reduced neuroactive steroids. *Pain* 114:429-443.
- Paul SM, Purdy RH (1992) Neuroactive steroids. *FASEB J* 6:2311-2322.
- Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsendardt AJ, Shu HJ, Izumi Y, Mennerick SJ, Zorumski CF (2013) The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. *J Neurosci* 33:17290-17300.
- Pinacho-Garcia, LM, Valdez RA, Araceli N, Marisa C, Segovia J, Romano MC (2020) The effect of finasteride and dutasteride on the synthesis of neurosteroids by glioblastoma cells. *Steroids* 155:108556.
- Romano C, Chen Q, Olney JW (1998) The intact isolated (ex vivo) retina as a model system for the study of excitotoxicity. *Prog Retin Eye Res* 17:465-483.
- Selvaraj V, Stocco DM, Tu LN (2015) Minireview: translocator protein (TSPO) and steroidogenesis: a reappraisal. *Mol Endocrinol* 29:490-501.
- Sodero AO, Trovo L, Iannilli F, Van Veldhoven P, Dotti CG, Martin MG (2011) Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature neurons: relevance for neuronal survival under stress and aging. *J Neurochem* 116:747-755.
- Spalding KL, Dharmarajan AM, Harvey AR (2005) Caspase-independent retinal ganglion cell death after target ablation in the neonatal rat. *Eur J Neurosci* 21:33-45.
- Sun MY, Linsendardt A, Emmett C, Eisenman LN, Izumi Y, Zorumski C, Mennerick S (2016) 24(S)-Hydroxycholesterol as a modulator of neuronal signaling and survival. *Neuroscientist* 22:132-144.
- Tokuda K, Zorumski CF, Izumi Y (2007) Effects of ascorbic acid on UV light-mediated photoreceptor damage in isolated rat retina. *Exp Eye Res* 84:537-543.
- Tokuda K, Zorumski CF, Izumi Y (2009) Involvement of illumination in indocyanine green toxicity after its washout in the ex vivo rat retina. *Retina* 29:371-379.
- Tokuda K, O'Dell KA, Izumi Y, Zorumski CF (2010) Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. *J Neurosci* 30:16788-16795.
- Tokuda K, Izumi Y, Zorumski CF (2011) Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation. *J Neurosci* 31:9905-9909.
- Tran NM, Shekhar K, Whitney IE, Jacobi A, Benhar I, Hong G, Yan W, Adiconis X, Arnold , Lee JM, Levin JZ, Lin D, Wang C, Lieber DM, Regev A, He Z, Sanes JR (2019) Single-cell profiles of retinal ganglion cells differing in resilience to injury reveal neuroprotective genes. *Neuron* 104:1039-1055.
- Wittmer LL, Hu Y, Kalkbrenner M, Evers AS, Zorumski CF, Covey DF (1996) Enantioselectivity of steroid-induced gamma-aminobutyric acid receptor modulation and anesthesia. *Mol Pharmacol* 50:1581-1586.
- Wong MY, Lewis M, Doherty JJ, Shi Y, Cashikar AG, Amelianchik A, Tymchuk S, Sullivan PM, Qian M, Covey DF, Petsko GA, Holtzman DM, Paul SM, Luo W (2020) 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. *J Neuroinflammation* 17:192.
- Yoshikawa T, Obayashi K, Miyata K, Ueda T, Kurumatani N, Saeki K, Ogata N (2019) Association between glaucomatous optic disc and depressive symptoms independent of light exposure profiles: a cross-sectional study of the HEIJO-KYO cohort. *Br J Ophthalmol* 103:1119-1122.
- Zhou B, Kreuzer J, Kumsta C, Wu L, Kamer KJ, Cedillo L, Zhang Y, Li S, Kacergis MC, Webster CM, Fejes-Toth G, Naray-Fejes-Toth A, Das S, Hansen M, Haas W, Soukas AA (2019) Mitochondrial permeability uncouples elevated autophagy and lifespan extension. *Cell* 177:299-314.
- Zorumski CF, Izumi Y (2012) NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. *Neurosci Biobehav Rev* 36:989-1000.
- Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. *Neurosci Biobehav Rev* 37:109-122.
- Zorumski CF, Mennerick S, Izumi Y (2014) Acute and chronic effects of ethanol on learning-related synaptic plasticity. *Alcohol* 48:1-17.
- Zorumski CF, Paul SM, Covey DF, Mennerick S (2019) Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. *Neurobiol Stress* 11:100196.